LeadCare blood lead tests recall expanded due to risk of falsely low results
The Food and Drug Administration and Magellan Diagnostics Inc. today expanded the ongoing recall of LeadCare II, LeadCare Plus and LeadCare Ultra Blood Lead Tests distributed between Oct. 27, 2020, and Aug. 19, 2021. FDA lists this as a Class I recall, the most serious type, due to a significant risk of falsely low results that could cause serious injuries, including in young children and pregnant individuals. FDA said clinicians should continue scheduled tests using other methods and retest children previously tested with a recalled kit. A replacement product is currently unavailable.
Related News Articles
Headline
The AHA Aug. 12 provided comments to the Consumer Product Safety Commission on its agenda and priorities for fiscal years 2027 and 2028, specifically…
Headline
The Food and Drug Administration Aug. 3 identified Class I recalls of two convenience kit products. Certain kits by Medline…
Headline
The Food and Drug Administration has identified a recall by Cook Medical of Zenith Alpha 2 Thoracic Endovascular Graft proximal components after Cook Medical…
Headline
The Food and Drug Administration has issued early alerts for certain Spectrum infusion pumps from Baxter and Abiomed Automated Impella Controllers. The agency…
Headline
The Food and Drug Administration has approved a new, first-of-its-kind semiannual HIV prevention medication, Gilead Sciences announced June 18. The company…
Headline
The White House Feb. 1 announced it placed tariffs on imported goods from Canada, Mexico and China. The tariffs for Mexico and Canada have since been delayed…